Genetic characterizations of driver genes of diffuse large B cell lymphoma

To identify novel genetic characterizations involved in PD-L1/2, other immune checkpoints and other driver genes in DLBCL patients and to identify patients that would benefit from immunotherapies and targeted therapies. Relevance: Immunotherapies and targeted therapies are currently the hottest topics for cancer treatment. A large number of clinical trials involved in checkpoint inhibitors and small molecule targeted drugs, including PD-1/PD-L1 antibodies and BTK inhibitors, are ongoing for various cancer types, including B cell lymphoma. Herein, we will try to identify some novel genetic variants for immune checkpoint molecules and some important oncogenes in DLBCL patients. Our findings are complementary for the genetic characterizations for these immune checkpoint molecules and oncogenes, and will also provide a theoretical foundation for the design of molecular targeted drugs and precision diagnosis and therapy.